Y-Intercept (HK)’s Clovis Oncology, Inc. CLVS Stock Holding History

Y-Intercept (HK)’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-11,630	Closed	-$21K	–	1371
2022 Q2	$21K	Buy	+11,630	New	+$17.2K	﹤0.01%	791

Other funds holding CLVS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Y-Intercept (HK)'s CLVS Position: Q3 2022 in Review

Y-Intercept (HK) sold out of Clovis Oncology, Inc. (CLVS) in Q3 2022, closing a stake of 11,630 shares — an estimated $21K sold.

Y-Intercept (HK) first reported a position in CLVS in Q2 2022 and held it in 1 quarter. The position peaked at $21K in Q2 2022. 103 funds tracked by Wall St. Rank hold CLVS as of Q3 2022.

Y-Intercept (HK) reported no remaining Clovis Oncology, Inc. position as of Q3 2022 after selling out during the quarter.
Y-Intercept (HK) sold 11,630 Clovis Oncology, Inc. shares in Q3 2022, an estimated $21K.
Y-Intercept (HK) first reported a position in Clovis Oncology, Inc. in Q2 2022 and held it in 1 quarter.
Y-Intercept (HK)'s Clovis Oncology, Inc. position peaked at $21K in Q2 2022.
103 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2022.

Based on Y-Intercept (HK)'s 13F filing for Q3 2022, filed 14 Feb 2023.